BioMAS
Tellurium based Drugs for Autoimmune Diseases
Company Name | Updating Date | Neurotech Category | Market Category | Target Market | Technologies | Company Founded Year | Company Number of Employees |
|---|---|---|---|---|---|---|---|
BioMAS | Biotechnology & Biopharmaceutical | 01/01/2000 | "1-10" |
BioMAS Ltd is a clinical-stage company focusing on the invention, development, and commercialization of tellurium-based compounds. The company’s lead molecules, AS101 and SAS, are small tellurium-based compounds developed for the treatment of various conditions. The molecules have integrin-inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies.
The company’s AS101/SAS drugs have demonstrated preclinical and clinical safety and efficacy for autoimmune-inflammatory diseases (psoriasis, arthritis, Crohn’s, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy.
A 15.4% stake in the company was acquired by Cosmo Pharmaceuticals (XSWS:COPN) for ILS 7 million on March 27, 2014.